A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...
The media may not want to admit it, but Trump's results speak for themselves: lower prices, more transparency, and real ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx ...
TMT, a new cancer drug, demonstrated strong results in phase 3 trials for advanced or recurrent endometrial cancer patients.
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade ...
The U.S. Supreme Court has declined to hear petitions from six major drugmakers challenging the Medicare Drug Price Negotiation Program, leaving in place lower court rulings that upheld the program ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
Merck (MRK.N), opens new tab said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial ...
Merck said on Monday its experimental drug met the main goals of a late-stage trial in patients with a cancer of the ...
Shares of Regeneron Pharmaceuticals are down about 11%, making it the worst performer on the S&P 500 today after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results